title: Patient-reported outcomes in subjects with painful trigeminal  neuralgia receiving pregabalin: evidence from medical practice in  primary care settings.
abstract: Effects of pregabalin (PGB) on patient-reported health outcomes were assessed in 65 PGB-naive subjects with trigeminal neuralgia refractory to previous analgesic therapy in a prospective, multicentre observational study carried out in primary care. Twelve weeks' monotherapy with PGB (n = 36) or add-on (n = 29), reduced baseline intensity of pain by a mean +/- S.D. of -40.0 +/- 22.1 mm [-55.4%, effect size (ES) 2.32; P < 0.0001] with 59.4% of responders (pain reduction >or= 50%), and produced 34.6 +/- 29.3 additional days with no/mild pain. Anxiety/depression symptoms decreased by -3.8 +/- 3.5 and -4.5 +/- 4.2 points (ES 0.95 and 1.02; P < 0.0001), respectively. PGB improved sleep by -17.9 +/- 19.6 points (ES 1.18; P < 0.0001) and improved patient functioning (Sheehan Disability Index) by decreasing overall scoring by -8.6 +/- 5.9 points (ES 1.59; P < 0.0001). Health state (EQ-5D) increased by 31.6 +/- 22.2 mm (ES 1.67; P < 0.0001), with 0.0388 +/- 0.0374 gained quality-adjusted life-years. In spite of the small sample size, results support the effectiveness of PGB for the improvement in pain and related health symptoms.
authors.affiliation: Pain Clinics, University Hospital La Princesa, Madrid, Spain. cperez.hlpr@salud.madrid.org
authors.forename: C
authors.initials: C
authors.lastname: Pérez
authors.forename: A
authors.initials: A
authors.lastname: Navarro
authors.forename: M T
authors.initials: MT
authors.lastname: Saldaña
authors.forename: S
authors.initials: S
authors.lastname: Martínez
authors.forename: J
authors.initials: J
authors.lastname: Rejas
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D004185:Disability Evaluation; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D000069583:Pregabalin; D011320:Primary Health Care; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014277:Trigeminal Neuralgia / Q000150:complications / Q000188:drug therapy*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid